Age | Gender | pT stage | pN stage | C stage | Grade | Ki67‡ | SOD2§ |
---|---|---|---|---|---|---|---|
Patient cohort # 1 (n = 53) | Â | Â | Â | Â | Â | Â | |
Age | 0.06 | -0.07 | 0.08 | 0.03 | na | 0.16 | 0.14 |
Gender | Â | 0.09 | -0.25 | -0.07 | na | 0.01 | 0.20 |
pT stage | Â | Â | 0.05 | 0.65 * | na | -0.18 | 0.49 * |
pN stage | Â | Â | Â | 0.49 * | na | 0.21 | -0.28 * |
C stage | Â | Â | Â | Â | na | -0.09 | 0.19 |
Grade | Â | Â | Â | Â | Â | na | na |
Ki67 | Â | Â | Â | Â | Â | Â | -0.01 |
SOD2 | Â | Â | Â | Â | Â | Â | Â |
Patient cohort #2 (n = 100) | Â | Â | Â | Â | Â | Â | |
Age | 0.12 | -0.05 | -0.10 | -0.01 | -0.01 | -0.01 | -0.16 |
Gender | Â | 0.11 | 0.04 | 0.11 | 0.07 | -0.05 | -0.02 |
pT stage | Â | Â | 0.42 * | 0.77 * | -0.16 | -0.01 | 0.04 |
pN stage | Â | Â | Â | 0.80 * | -0.05 | 0.09 | -0.35 * |
C stage | Â | Â | Â | Â | -0.07 | 0.05 | -0.21 * |
Grade | Â | Â | Â | Â | Â | 0.05 | -0.30 * |
Ki67 | Â | Â | Â | Â | Â | Â | -0.28 * |
SOD2 | Â | Â | Â | Â | Â | Â | Â |